A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical genitourinary …, 2013 - Elsevier
Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
AJ Armstrong, T Shen, S Halabi, G Kemeny, RL Bitting… - 2013 - ascopubs.org
105 Background: PTEN loss is common in advanced prostate cancer, leading to constitutive
activation of the PI3 Kinase pathway. Temsirolimus blocks mTOR/TORC1, a key signaling …
activation of the PI3 Kinase pathway. Temsirolimus blocks mTOR/TORC1, a key signaling …
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
AJ Armstrong, T Shen, S Halabi… - Clinical …, 2013 - clinical-genitourinary-cancer.com
Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical Genitourinary …, 2013 - infona.pl
Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer,
leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian …
leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian …
[引用][C] A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical Genitourinary …, 2013 - cir.nii.ac.jp
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical Genitourinary …, 2013 - europepmc.org
Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
AJ Armstrong, T Shen, S Halabi… - Clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical Genitourinary …, 2013 - hero.epa.gov
BACKGROUND: Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …